| Year |
Citation |
Score |
| 2023 |
Tian M, Wei JS, Shivaprasad N, Highfill SL, Gryder BE, Milewski D, Brown GT, Moses L, Song H, Wu JT, Azorsa P, Kumar J, Schneider D, Chou HC, Song YK, ... ... Orentas RJ, et al. Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma. Cell Reports. Medicine. 101212. PMID 37774704 DOI: 10.1016/j.xcrm.2023.101212 |
0.441 |
|
| 2023 |
Masih KE, Gardner RA, Chou HC, Abdelmaksoud A, Song YK, Mariani L, Gangalapudi V, Gryder BE, Wilson AL, Adebola SO, Stanton BZ, Wang C, Milewski D, Kim YY, Tian M, ... ... Orentas RJ, et al. A stem cell epigenome is associated with primary nonresponse to CD19 CAR T-cells in pediatric acute lymphoblastic leukemia. Blood Advances. PMID 36607839 DOI: 10.1182/bloodadvances.2022008977 |
0.475 |
|
| 2022 |
Palani HK, Arunachalam AK, Yasar M, Venkatraman A, Kulkarni U, Lionel SA, Selvarajan S, Korula A, Abraham A, George B, Adair JE, Orentas R, Dropulic B, Mathews V. Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India. Bone Marrow Transplantation. PMID 36347999 DOI: 10.1038/s41409-022-01866-5 |
0.417 |
|
| 2022 |
Vitanza NA, Wilson AL, Huang W, Seidel K, Brown C, Gustafson JA, Yokoyama JK, Johnson AJ, Baxter BA, Koning RW, Reid AN, Meechan M, Biery MC, Myers C, Rawlings-Rhea SD, ... ... Orentas RJ, et al. Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety. Cancer Discovery. PMID 36259971 DOI: 10.1158/2159-8290.CD-22-0750 |
0.397 |
|
| 2022 |
Sullivan PM, Kumar R, Li W, Hoglund V, Wang L, Zhang Y, Shi M, Baek D, Cheuk A, Jensen MC, Khan J, Dimitrov DS, Orentas RJ. FGFR4-targeted chimeric antigen receptors (CARs) combined with anti-myeloid poly-pharmacy effectively treats orthotopic rhabdomyosarcoma. Molecular Cancer Therapeutics. PMID 35877472 DOI: 10.1158/1535-7163.MCT-22-0059 |
0.453 |
|
| 2022 |
Wang L, Zhang Y, Anderson E, Lamble A, Orentas RJ. Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line. Frontiers in Immunology. 13: 825364. PMID 35222407 DOI: 10.3389/fimmu.2022.825364 |
0.542 |
|
| 2021 |
Maschan M, Caimi PF, Reese-Koc J, Sanchez GP, Sharma AA, Molostova O, Shelikhova L, Pershin D, Stepanov A, Muzalevskii Y, Suzart VG, Otegbeye F, Wald D, Xiong Y, Wu D, ... ... Orentas R, et al. Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. Nature Communications. 12: 7200. PMID 34893603 DOI: 10.1038/s41467-021-27312-6 |
0.455 |
|
| 2021 |
Brohl AS, Sindiri S, Wei JS, Milewski D, Chou HC, Song YK, Wen X, Kumar J, Reardon HV, Mudunuri US, Collins JR, Nagaraj S, Gangalapudi V, Tyagi M, Zhu YJ, ... ... Orentas RJ, et al. Immuno-transcriptomic profiling of extracranial pediatric solid malignancies. Cell Reports. 37: 110047. PMID 34818552 DOI: 10.1016/j.celrep.2021.110047 |
0.367 |
|
| 2021 |
Vitanza NA, Johnson AJ, Wilson AL, Brown C, Yokoyama JK, Künkele A, Chang CA, Rawlings-Rhea S, Huang W, Seidel K, Albert CM, Pinto N, Gust J, Finn LS, Ojemann JG, ... ... Orentas RJ, et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nature Medicine. PMID 34253928 DOI: 10.1038/s41591-021-01404-8 |
0.387 |
|
| 2021 |
Zhang HF, Hughes CS, Li W, He JZ, Surdez D, El-Naggar AM, Cheng H, Prudova A, Delaidelli A, Negri GL, Li X, Orum-Madsen MS, Lizardo MM, Oo HZ, Colborne S, ... ... Orentas RJ, et al. Proteomic screens for suppressors of anoikis identify IL1RAP as a promising surface target in Ewing sarcoma. Cancer Discovery. PMID 34021002 DOI: 10.1158/2159-8290.CD-20-1690 |
0.3 |
|
| 2021 |
Webster B, Xiong Y, Hu P, Wu D, Alabanza L, Orentas RJ, Dropulic B, Schneider D. Self-driving armored CAR-T cells overcome suppressive milieu and eradicate CD19+ Raji lymphoma in preclinical models. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 33974997 DOI: 10.1016/j.ymthe.2021.05.006 |
0.444 |
|
| 2021 |
Schneider D, Xiong Y, Wu D, Hu P, Alabanza L, Steimle B, Mahmud H, Anthony-Gonda K, Krueger W, Zhu Z, Dimitrov DS, Orentas RJ, Dropulić B. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Science Translational Medicine. 13. PMID 33762438 DOI: 10.1126/scitranslmed.abc6401 |
0.552 |
|
| 2020 |
Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nature Medicine. PMID 33020647 DOI: 10.1038/s41591-020-1081-3 |
0.514 |
|
| 2020 |
Jackson Z, Roe A, Sharma AA, Lopes FBTP, Talla A, Kleinsorge-Block S, Zamborsky K, Schiavone J, Manjappa S, Schauner R, Lee G, Liu R, Caimi PF, Xiong Y, Krueger W, ... ... Orentas R, et al. Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma. Frontiers in Immunology. 11: 1941. PMID 32849651 DOI: 10.3389/Fimmu.2020.01941 |
0.604 |
|
| 2020 |
Caimi P, Reese JS, Otegbeye F, Schneider D, Bakalarz KL, Boughan KM, Cooper B, Galloway E, Gallogly M, Kruger W, Worden A, Kadan M, Lopes FBTP, Sharma A, Malek E, ... ... Orentas R, et al. On Site Manufacture of AntiCD19 CAR-T Cells. Responses in Subjects with Rapidly Progressive Refractory Lymphomas. Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.478 |
0.484 |
|
| 2020 |
Ahmed N, Caimi P, Reese JS, Otegbeye F, Patel S, Schneider D, Boughan KM, Cooper B, Gallogly M, Kruger W, Worden A, Kadan M, Lopes FBTP, Sharma A, Malek E, ... ... Orentas R, et al. Prophylactic Tocilizumab in Patients with Relapsed Refractory Lymphoma Treated with Anti CD19 Chimeric Antigen Receptor T-Cell Therapy Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.447 |
0.515 |
|
| 2019 |
Ravanpay AC, Gust J, Johnson AJ, Rolczynski LS, Cecchini M, Chang CA, Hoglund VJ, Mukherjee R, Vitanza NA, Orentas RJ, Jensen MC. EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma. Oncotarget. 10: 7080-7095. PMID 31903167 DOI: 10.18632/Oncotarget.27389 |
0.525 |
|
| 2019 |
Bari R, Granzin M, Tsang KS, Roy A, Krueger W, Orentas R, Pfeifer R, Moeker N, Verhoeyen E, Dropulic B, Leung W. A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy. Frontiers in Immunology. 10: 2001. PMID 31507603 DOI: 10.3389/Fimmu.2019.02001 |
0.516 |
|
| 2019 |
Anthony-Gonda K, Bardhi A, Ray A, Flerin N, Li M, Chen W, Ochsenbauer C, Kappes JC, Krueger W, Worden A, Schneider D, Zhu Z, Orentas R, Dimitrov DS, Goldstein H, et al. Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model. Science Translational Medicine. 11. PMID 31391322 DOI: 10.1126/Scitranslmed.Aav5685 |
0.352 |
|
| 2019 |
Finney OC, Brakke HM, Rawlings-Rhea S, Hicks R, Doolittle D, Lopez M, Futrell RB, Orentas RJ, Li D, Gardner RA, Jensen MC. CD19 CAR T cell product and disease attributes predict leukemia remission durability. The Journal of Clinical Investigation. 130. PMID 30860496 DOI: 10.1172/Jci125423 |
0.539 |
|
| 2019 |
Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, Sotillo E, Labanieh L, Lee DW, Orentas RJ, Dimitrov DS, et al. CAR T cells targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30655315 DOI: 10.1158/1078-0432.Ccr-18-0432 |
0.534 |
|
| 2019 |
Shah NN, Zhu F, Schneider D, Taylor C, Krueger W, Worden A, Longo WL, Hamadani M, Fenske T, Johnson B, Dropulic B, Orentas R, Hari P. Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma. Journal of Clinical Oncology. 37: 2510-2510. DOI: 10.1200/Jco.2019.37.15_Suppl.2510 |
0.487 |
|
| 2019 |
Caimi PF, Reese J, Otegbeye F, Schneider D, Bakalarz K, Boughan KM, Cooper B, Gallogly MM, Galloway E, Kruger W, Worden A, Kadan M, Lopes FB, Sharma A, Malek E, ... ... Orentas R, et al. Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas Blood. 134: 4074-4074. DOI: 10.1182/Blood-2019-131300 |
0.509 |
|
| 2019 |
Masih KE, Gardner R, Gryder B, Abdallah A, Lack J, Stanton B, Wilson A, Sindiri S, Song Y, Rae Z, Kelly M, Chaoyu W, Wen X, Cheuk A, Wei J, ... ... Orentas R, et al. Detailed Multi-Method Analysis of Bone Marrow from Pediatric Pre-B-ALL Patients Prior to CD19-CAR-T Therapy Subsequently Evidencing Overt CAR-T Resistance Blood. 134: 2744-2744. DOI: 10.1182/Blood-2019-130796 |
0.532 |
|
| 2019 |
Molostova O, Shelikhova L, Schneider D, Khismatullina R, Muzalevsky Y, Kazachenok A, Preussner L, Rauser G, Abugova J, Kurnikova E, Pershin D, Zubachenko V, Popov A, Illarionova O, Miakova N, ... ... Orentas R, et al. Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy with Low Toxicities Blood. 134: 2625-2625. DOI: 10.1182/Blood-2019-130370 |
0.514 |
|
| 2019 |
Masih KE, Gardner R, Gryder BE, Lack J, Stanton BZ, Wilson A, Finney O, Sindiri S, Song Y, Rae Z, Kelly M, Wang C, Wen X, Cheuk A, Wei JS, ... ... Orentas R, et al. Abstract LB-056: An integrated genomic, epigenetic, proteomic, and single cell analysis of pediatric B cell acute lymphoblastic leukemia to elucidate resistance mechanisms to CD19 CAR T cell therapy Immunology. DOI: 10.1158/1538-7445.Sabcs18-Lb-056 |
0.503 |
|
| 2019 |
Anthony-Gonda K, Bardhi A, Ray A, Krueger W, Schneider D, Zhu Z, Orentas R, Dimitrov D, Goldstein H, Dropulic B. Multispecific anti-HIV duoCAR-T cell therapy mediates robust HIV suppression and elimination of HIV-infected cells in humanised mice Journal of Virus Eradication. 5: 47. DOI: 10.1016/S2055-6640(20)30196-5 |
0.301 |
|
| 2019 |
Zhu F, Shah N, Schneider D, Xu H, Chaney K, Luib L, Keever-Taylor C, Dropulic B, Orentas R, Hari P, Johnson B. Results of point-of-care manufacturing of bispecific chimeric antigen receptor (CAR) LV20.19 CAR-TCELLS in a phase i study for relapsed/refractory (R/R), non-hodgkin lymphoma (NHL) Cytotherapy. 21: S10-S11. DOI: 10.1016/J.Jcyt.2019.03.568 |
0.587 |
|
| 2019 |
Shah NN, Zhu F, Keever-Taylor C, Schneider D, Kruger W, Worden A, Hamadani M, Fenske TS, Johnson BD, Dropulic B, Orentas R, Hari P. Clinical Results of a First-in-Human Phase 1 Study of Point-of-Care Manufactured Bispecific Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-20.19-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma (NHL) Biology of Blood and Marrow Transplantation. 25: S63-S64. DOI: 10.1016/J.Bbmt.2018.12.146 |
0.522 |
|
| 2019 |
Caimi PF, Reese-Koc JS, Otegbeye F, Schneider D, Chamoun K, Boughan KM, Cooper BW, Galloway E, Gallogly MM, Kruger W, Worden A, Kadan M, Malek E, Metheny L, Tomlinson B, ... ... Orentas R, et al. PHASE 1 STUDY OF ANTICD19 CAR-T CELLS WITH TNFα TRANSMEMBRANE DOMAIN AND 41BB, CD3ζ COSTIMULATORY DOMAINS. RESPONSES IN SUBJECTS WITH RAPIDLY PROGRESSIVE LYMPHOMA Hematological Oncology. 37: 305-306. DOI: 10.1002/Hon.115_2630 |
0.374 |
|
| 2018 |
Schneider D, Xiong Y, Hu P, Wu D, Chen W, Ying T, Zhu Z, Dimitrov DS, Dropulic B, Orentas RJ. A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia. Frontiers in Oncology. 8: 539. PMID 30524966 DOI: 10.3389/Fonc.2018.00539 |
0.571 |
|
| 2018 |
Molostova O, Shelikhova L, Muzalevsky Y, Kazachenok A, Pershin D, Kurnikova E, Popov A, Dropulic B, Shneider D, Orentas R, Alex R, Essl M, Miakova N, Litvinov D, Karachunskiy A, et al. Title Point-of-Care Production of CD19 CAR-T Cells in an Automated Closed-System: Report of First Clinical Experience Blood. 132: 5202-5202. DOI: 10.1182/Blood-2018-99-118282 |
0.562 |
|
| 2018 |
Zhu F, Shah NN, Schneider D, Xu H, Chaney K, Luib L, Keever-Taylor CA, Dropulic B, Orentas R, Hari P, Johnson B. Point-of-Care Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells in a Standard Academic Cell Processing Facility for a Phase I Clinical Trial in Relapsed, Refractory NHL Blood. 132: 4553-4553. DOI: 10.1182/Blood-2018-99-116566 |
0.588 |
|
| 2018 |
Shah NN, Zhu F, Taylor C, Schneider D, Krueger W, Worden A, Yim S, Fenske TS, Hamadani M, Johnson B, Dropulic B, Orentas R, Hari P. A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma Blood. 132: 4193-4193. DOI: 10.1182/Blood-2018-99-110194 |
0.513 |
|
| 2018 |
Schneider D, Xiong Y, Chen W, Zhu Z, Wu D, Hwang J, Dimitrov DS, Dropulic B, Orentas RJ. Abstract 2561: Fully human immunoglobulin heavy chain only-derived CD33 CAR for the treatment of acute myeloid leukemia Cancer Research. 78: 2561-2561. DOI: 10.1158/1538-7445.Am2018-2561 |
0.569 |
|
| 2017 |
Zhu F, Shah N, Xu H, Schneider D, Orentas R, Dropulic B, Hari P, Keever-Taylor CA. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy. PMID 29287970 DOI: 10.1016/J.Jcyt.2017.09.005 |
0.549 |
|
| 2017 |
Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, et al. Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. Cancer Immunology, Immunotherapy : Cii. PMID 29264697 DOI: 10.1007/S00262-017-2102-Z |
0.407 |
|
| 2017 |
Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, Shalabi H, Fountaine TJ, Shern JF, Majzner RG, Stroncek DF, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nature Medicine. PMID 29155426 DOI: 10.1038/Nm.4441 |
0.54 |
|
| 2017 |
Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, et al. Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. Cancer Immunology, Immunotherapy : Cii. PMID 29052782 DOI: 10.1007/S00262-017-2073-0 |
0.557 |
|
| 2017 |
Orentas RJ, Sindiri S, Duris C, Wen X, He J, Wei JS, Jarzembowski J, Khan J. Paired Expression Analysis of Tumor Cell Surface Antigens. Frontiers in Oncology. 7: 173. PMID 28871274 DOI: 10.3389/Fonc.2017.00173 |
0.523 |
|
| 2017 |
Walker AJ, Majzner RG, Zhang L, Wanhainen K, Long AH, Nguyen SM, Lopomo P, Vigny M, Fry TJ, Orentas RJ, Mackall CL. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 28676342 DOI: 10.1016/J.Ymthe.2017.06.008 |
0.544 |
|
| 2017 |
Schneider D, Xiong Y, Wu D, Nӧlle V, Schmitz S, Haso W, Kaiser A, Dropulic B, Orentas RJ. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. Journal For Immunotherapy of Cancer. 5: 42. PMID 28515942 DOI: 10.1186/S40425-017-0246-1 |
0.499 |
|
| 2017 |
Schneider D, Xiong Y, Wu D, Dropulic B, Orentas R. Abstract 3746: Plasma membrane spanning and linker-domains from tumor necrosis factor receptor superfamily (TNFRSF) proteins provide novel functionality to chimeric antigen receptors (CARs) expressed in human T cells Immunology. 77: 3746-3746. DOI: 10.1158/1538-7445.Am2017-3746 |
0.422 |
|
| 2017 |
Schneider D, Xiong Y, Wu D, Nolle V, Schmitz S, Kaiser A, Dropulic B, Orentas R. Leukemia Cell Surface Antigen Modulation Induced By Dual CD19/CD20 Chimeric Antigen Receptor (CAR)-T Cells Biology of Blood and Marrow Transplantation. 23: S250-S251. DOI: 10.1016/J.Bbmt.2016.12.418 |
0.584 |
|
| 2017 |
Shah N, Zhu F, Xu H, Schneider D, Orentas R, Dropulic B, Hari P, Keever-Taylor C. Dual Targeted CD20/19 CAR-T Cell Production Using the Clinimacs® Prodigy System Biology of Blood and Marrow Transplantation. 23: S162. DOI: 10.1016/J.Bbmt.2016.12.274 |
0.56 |
|
| 2016 |
Long AH, Highfill SL, Cui Y, Smith JP, Walker AJ, Ramakrishna S, El-Etriby R, Galli S, Tsokos M, Orentas RJ, Mackall CL. Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunology Research. PMID 27549124 DOI: 10.1158/2326-6066.Cir-15-0230 |
0.606 |
|
| 2016 |
Zhu F, Shah NN, Xu H, Schneider D, Orentas R, Dropulic B, Hari P, Keever-Taylor CA. CAR-T Cell Production Using the Clinimacs® Prodigy System Blood. 128: 5724-5724. DOI: 10.1182/Blood.V128.22.5724.5724 |
0.6 |
|
| 2016 |
Shalabi H, Qin H, Wanhainen K, Smith J, Orentas R, Shah NN, Maude SL, Tasian SK, Teachey DT, Khan J, Fry TJ. Preclinical Development of a T-Cell ALL CAR Demonstrates That Differences in CAR Membrane Distribution May Impact Efficacy Blood. 128: 4019-4019. DOI: 10.1182/Blood.V128.22.4019.4019 |
0.596 |
|
| 2016 |
Majzner RG, Walker AJ, Murgai M, Zhang L, Long AH, Wanhainen KM, Orentas RJ, Mackall CL. Abstract 2648: Chimeric antigen receptor T-cell therapy against anaplastic lymphoma kinase (ALK) is limited by target antigen density and CAR surface expression Cancer Research. 76: 2648-2648. DOI: 10.1158/1538-7445.Am2016-2648 |
0.566 |
|
| 2016 |
Schneider D, Xiong Y, Wu D, Dropulic B, Orentas R. Abstract 2297: Tandem anti-CD20 and -CD19 scFV-based chimeric antigen receptors (CARs) mitigate tumor escape in hematologic malignancies Cancer Research. 76: 2297-2297. DOI: 10.1158/1538-7445.Am2016-2297 |
0.648 |
|
| 2016 |
Shivaprasad N, Xiong Y, Yohe M, Schneider D, Shern J, Baskar S, Dimitrov D, Sorenson P, Orentas R, Khan J. 649. Developing FGFR4 Chimeric Antigen Receptor CAR T Cell Therapy Against Rhabdomyosarcoma Molecular Therapy. 24: S257-S258. DOI: 10.1016/S1525-0016(16)33457-8 |
0.49 |
|
| 2016 |
Xiong Y, Wu D, Dropulic B, Orentas R, Schneider D. 648. Mitigating Tumor Escape: Tandem Anti-CD20- and CD19 SCFV-Based Chimeric Antigen Receptors (CARs) in Leukemia/Lymphoma Molecular Therapy. 24. DOI: 10.1016/S1525-0016(16)33456-6 |
0.648 |
|
| 2015 |
Orentas RJ, Mackall CL. Emerging Immunotherapies for Cancer and Their Potential for Application in Pediatric Oncology. Critical Reviews in Oncogenesis. 20: 315-27. PMID 26349422 DOI: 10.1615/Critrevoncog.2015013861 |
0.396 |
|
| 2015 |
Qin H, Cho M, Haso W, Zhang L, Tasian SK, Oo HZ, Negri GL, Lin Y, Zou J, Mallon BS, Maude S, Teachey DT, Barrett DM, Orentas RJ, Daugaard M, et al. Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood. PMID 26041741 DOI: 10.1182/Blood-2014-11-612903 |
0.583 |
|
| 2015 |
Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, Kaplan RN, Patterson GH, Fry TJ, Orentas RJ, Mackall CL. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nature Medicine. 21: 581-90. PMID 25939063 DOI: 10.1038/Nm.3838 |
0.578 |
|
| 2015 |
Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet (London, England). 385: 517-28. PMID 25319501 DOI: 10.1016/S0140-6736(14)61403-3 |
0.55 |
|
| 2015 |
Schneider D, Xiong Y, Roy A, Kaiser A, Dropulic B, Orentas R. Minimizing leukemia escape: implementing a dual anti-CD20- and CD19-scFv-based chimeric antigen receptor (CAR) Journal For Immunotherapy of Cancer. 3: 122. DOI: 10.1186/2051-1426-3-S2-P122 |
0.635 |
|
| 2015 |
Long AH, Haso WM, Smith JP, Walker AJ, Fry TJ, Orentas RJ, Mackall CL. Abstract 4702: 4-1BB costimulation ameliorates exhaustion and prolongs in vivo persistence of chimeric antigen receptor (CAR) expressing T cells Cancer Research. 75: 4702-4702. DOI: 10.1158/1538-7445.Am2015-4702 |
0.624 |
|
| 2015 |
Walker AJ, Zhang L, Long AH, Orentas RJ, Mackall CL. Abstract 3140: Antigen-induced downmodulation is associated with diminished efficacy of a novel chimeric antigen receptor targeting anaplastic lymphoma kinase Cancer Research. 75: 3140-3140. DOI: 10.1158/1538-7445.Am2015-3140 |
0.634 |
|
| 2014 |
Orentas RJ, Nordlund J, He J, Sindiri S, Mackall C, Fry TJ, Khan J. Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison. Frontiers in Oncology. 4: 134. PMID 24959420 DOI: 10.3389/Fonc.2014.00134 |
0.604 |
|
| 2014 |
Kroesen M, Nierkens S, Ansems M, Wassink M, Orentas RJ, Boon L, den Brok MH, Hoogerbrugge PM, Adema GJ. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma. International Journal of Cancer. 134: 1335-45. PMID 24038106 DOI: 10.1002/Ijc.28463 |
0.465 |
|
| 2014 |
Walker A, Lopomo P, Babbitt W, Vigny M, Mackall C, Orentas R. Targeting high-risk pediatric solid tumors with CAR T cells directed against ALK (anaplastic lymphoma kinase, CD246) Journal For Immunotherapy of Cancer. 2: 40. DOI: 10.1186/2051-1426-2-S3-P40 |
0.595 |
|
| 2014 |
Tschernia N, Orentas R, Mackall C. Chondroitin sulfate proteoglycan 4 specific chimeric antigen receptor therapy for pediatric solid tumors Journal For Immunotherapy of Cancer. 2: 39. DOI: 10.1186/2051-1426-2-S3-P39 |
0.574 |
|
| 2014 |
Baskar S, Zhu Z, Labitigan RL, Ovanesian M, Orentas RJ, Li SQ, Marielle YE, Shern J, Dimitrov DS, Maris J, Mackall C, Javed K. Abstract 652: Development and characterization of anti-FGFR4 monoclonal antibodies as therapeutic agents for human rhabdomyosarcoma Cancer Research. 74: 652-652. DOI: 10.1158/1538-7445.Am2014-652 |
0.415 |
|
| 2014 |
Long A, Orentas RJ, Mackall CL. Abstract 2943: 14g2a-based GD2-specific chimeric antigen receptors (CARs) constitutively signal, leading to rapidly induced T-cell exhaustion and poor antitumor efficacyin vivo Cancer Research. 74: 2943-2943. DOI: 10.1158/1538-7445.Am2014-2943 |
0.601 |
|
| 2014 |
Walker A, Lopomo P, Babbitt W, Vigny M, Mackall CL, Orentas RJ. Abstract 2799: Adoptive immunotherapy for pediatric solid tumors with CAR-T cells (chimeric antigen receptor bearing T cells) targeting ALK (anaplastic lymphoma kinase, CD246) Cancer Research. 74: 2799-2799. DOI: 10.1158/1538-7445.Am2014-2799 |
0.588 |
|
| 2013 |
Zhang H, Maric I, DiPrima MJ, Khan J, Orentas RJ, Kaplan RN, Mackall CL. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood. 122: 1105-13. PMID 23757729 DOI: 10.1182/Blood-2012-08-449413 |
0.474 |
|
| 2013 |
Long AH, Haso WM, Orentas RJ. Lessons learned from a highly-active CD22-specific chimeric antigen receptor. Oncoimmunology. 2: e23621. PMID 23734316 DOI: 10.4161/Onci.23621 |
0.511 |
|
| 2013 |
Orentas RJ. Reading the tea leaves of tumor-mediated immunosuppression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 955-7. PMID 23430024 DOI: 10.1158/1078-0432.Ccr-12-3792 |
0.345 |
|
| 2013 |
Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 121: 1165-74. PMID 23243285 DOI: 10.1182/Blood-2012-06-438002 |
0.516 |
|
| 2013 |
Orentas RJ, Lopomo P, Babbitt W, Vigny M, Mackall CL. ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors Journal For Immunotherapy of Cancer. 1: 27. DOI: 10.1186/2051-1426-1-S1-P27 |
0.54 |
|
| 2013 |
Highfill SL, Long AH, Orentas RJ, Mackall CL. Neutralization of murine myeloid-derived suppressor cells enhances the efficacy of a chimeric antigen receptor T-cells directed against pediatric solid tumors Journal For Immunotherapy of Cancer. 1: 265. DOI: 10.1186/2051-1426-1-S1-P265 |
0.567 |
|
| 2013 |
Long AH, Orentas RJ, Mackall CL. Enhanced glycolytic metabolism is associated with exhaustion and poor antitumor efficacy in a xenograft model of chimeric antigen receptor T cell therapy for sarcoma Journal For Immunotherapy of Cancer. 1: 21. DOI: 10.1186/2051-1426-1-S1-P21 |
0.562 |
|
| 2013 |
Qin H, Monica C, Haso W, Zhang L, Barrett DM, Orentas RJ, Grupp SA, Fry TJ. Pre-Clinical Development Of a Novel Chimerical Antigen Receptor Targeting High-Risk Pediatric ALL Over-Expressing Tslpr Blood. 122: 2665-2665. DOI: 10.1182/Blood.V122.21.2665.2665 |
0.566 |
|
| 2013 |
Orentas RJ, Mackall CL. Synthetic Chimeric Antigen Receptors (CARs) Rapidly Induce Exhaustion and Augmented Glycolytic Metabolism In Human T Cells and Implicate Persistent CD28 Signaling As a Driver Of Exhaustion In Human T Cells Blood. 122: 192-192. DOI: 10.1182/Blood.V122.21.192.192 |
0.624 |
|
| 2013 |
Qin H, Zhang L, Orentas RJ, Fry TJ. CD22-Targeted Chimeric Antigen Receptor (CAR) T Cells Containing The 4-1BB Costimulatory Domain Demonstrate Enhanced Persistence and Superior Efficacy Against B-Cell Precursor Acute Lymphoblastic Leukemia (ALL) Compared To Those Containing CD28 Blood. 122: 1431-1431. DOI: 10.1182/Blood.V122.21.1431.1431 |
0.607 |
|
| 2013 |
Long AH, Highfill SL, Haso WM, Orentas RJ, Mackall CL. Abstract 3974: Evaluating the susceptibility of solid tumors to chimeric antigen receptor modified T cell therapies. Cancer Research. 73: 3974-3974. DOI: 10.1158/1538-7445.Am2013-3974 |
0.625 |
|
| 2012 |
Orentas RJ, Yang JJ, Wen X, Wei JS, Mackall CL, Khan J. Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers. Frontiers in Oncology. 2: 194. PMID 23251904 DOI: 10.3389/Fonc.2012.00194 |
0.454 |
|
| 2012 |
Orentas RJ, Lee DW, Mackall C. Immunotherapy targets in pediatric cancer. Frontiers in Oncology. 2: 3. PMID 22645714 DOI: 10.3389/Fonc.2012.00003 |
0.461 |
|
| 2012 |
Lee DW, Barrett DM, Mackall C, Orentas R, Grupp SA. The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2780-90. PMID 22589486 DOI: 10.1158/1078-0432.Ccr-11-1920 |
0.467 |
|
| 2012 |
Stauffer JK, Orentas RJ, Lincoln E, Khan T, Salcedo R, Hixon JA, Back TC, Wei JS, Patidar R, Song Y, Hurd L, Tsokos M, Lai EW, Eisenhofer G, Weiss W, et al. High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: new tools for pediatric drug discovery. Cancer Investigation. 30: 343-63. PMID 22571338 DOI: 10.3109/07357907.2012.664670 |
0.371 |
|
| 2012 |
Haso W, Lee DW, Pastan I, Dimitrov DS, Mackall CL, Orentas RJ. A New High Activity Anti-CD22 Chimeric Antigen Receptor (CAR) Targeting B Cell Leukemia. Blood. 120: 2611-2611. DOI: 10.1182/Blood.V120.21.2611.2611 |
0.56 |
|
| 2012 |
Haso W, Lee D, Morgan R, Pastan I, Mackall C, Orentas RJ. Abstract 3504: Generation and optimization of a chimeric antigen receptor against human CD22: A new immunotherapeutic agent for adoptive immunotherapy Cancer Research. 72: 3504-3504. DOI: 10.1158/1538-7445.Am2012-3504 |
0.554 |
|
| 2011 |
Ramakrishna S, Gottschalk S, Morgan R, Dotti G, Brenner MK, Orentas R, Mackall C. Can the well-credentialed neuroblastoma tumor antigen GD2 be exploited for T-cell-based immunotherapy of pediatric sarcomas? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 9531. PMID 28019777 DOI: 10.1200/Jco.2011.29.15_Suppl.9531 |
0.577 |
|
| 2011 |
Meadors JL, Cui Y, Chen QR, Song YK, Khan J, Merlino G, Tsokos M, Orentas RJ, Mackall CL. Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy. Pediatric Blood & Cancer. 57: 921-9. PMID 21462302 DOI: 10.1002/Pbc.23048 |
0.489 |
|
| 2011 |
Zheng J, Orentas R, Yan X, Liu H. Humoral immune response induced by an engineered cell-based neuroblastoma vaccine with or without CD25 blockade Acta Biochimica Et Biophysica Sinica. 43: 124-132. PMID 21266542 DOI: 10.1093/Abbs/Gmq123 |
0.546 |
|
| 2011 |
Lee DW, Kochenderfer JN, Orentas RJ, Gardner EG, Mackall CL. ALL Xenografts Reveal the Importance of Anti-CD19-Chimeric Antigen Receptor Cell Dose, Cell Persistence and Surprising Antitumor Activity of CD4+ Anti-CD19-CAR T Cells in Eradicating Pediatric Acute Lymphocytic Leukemia In Vivo Blood. 118: 574-574. DOI: 10.1182/Blood.V118.21.574.574 |
0.625 |
|
| 2011 |
Orentas RJ, Haso W, Morgan RA, Pastan I, Mackall CL. Generation and Optimization of a Chimeric Antigen Receptor Against CD22: A New Immunotherapeutic Agent for Treating B Lineage Leukemia and Lymphoma Blood. 118: 4313-4313. DOI: 10.1182/Blood.V118.21.4313.4313 |
0.555 |
|
| 2010 |
Kohler ME, Johnson BD, Palen K, Chen QR, Khan J, Orentas RJ. Tumor antigen analysis in neuroblastoma by serological interrogation of bioinformatic data. Cancer Science. 101: 2316-24. PMID 20718755 DOI: 10.1111/J.1349-7006.2010.01694.X |
0.472 |
|
| 2010 |
Kohler ME, Hallett WH, Chen QR, Khan J, Johnson BD, Orentas RJ. Early expression of stem cell-associated genes within the CD8 compartment after treatment with a tumor vaccine. Cellular Immunology. 265: 65-73. PMID 20692654 DOI: 10.1016/J.Cellimm.2010.07.004 |
0.556 |
|
| 2010 |
Norell H, Zhang Y, McCracken J, Martins da Palma T, Lesher A, Liu Y, Roszkowski JJ, Temple A, Callender GG, Clay T, Orentas R, Guevara-Patiño J, Nishimura MI. CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting. Cancer Immunology, Immunotherapy : Cii. 59: 851-62. PMID 20052466 DOI: 10.1007/S00262-009-0810-8 |
0.63 |
|
| 2010 |
Lee DW, Kochenderfer JN, Rader C, Orentas RJ, Mackall CL. Novel Antigen-Specific Expansion of T Cells Transduced with a CD19 Chimeric Antigen Receptor Blood. 116: 3262-3262. DOI: 10.1182/Blood.V116.21.3262.3262 |
0.624 |
|
| 2010 |
Capitini CM, Meadors JL, Cho MM, Orentas RJ, Mackall CL, Fry TJ. 4-1BBL-Expressing aAPCs Attenuate IL-15-Induced NK Cell Expansion and Cytokine Production In Vitro but Induce NK Cell-Mediated Gvhd In Vivo Blood. 116: 2536-2536. DOI: 10.1182/Blood.V116.21.2536.2536 |
0.346 |
|
| 2010 |
Meadors JL, Cui Y, Poon R, Zhang H, Fewkes NM, Orentas RJ, Merlino G, Khan J, Chen Q, Song YK, Mackall CL. Abstract 3420: Whole cell vaccines prevent primary tumor growth and metastases in murine embryonal rhabdomyosarcoma Cancer Research. 70: 3420-3420. DOI: 10.1158/1538-7445.Am10-3420 |
0.497 |
|
| 2009 |
Zheng J, Jing W, Orentas RJ. Discovery of YB-1 as a new immunological target in neuroblastoma by vaccination in the context of regulatory T cell blockade. Acta Biochimica Et Biophysica Sinica. 41: 980-90. PMID 20011972 DOI: 10.1093/Abbs/Gmp092 |
0.586 |
|
| 2008 |
Yan X, Johnson BD, Orentas RJ. Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L. Journal of Immunology (Baltimore, Md. : 1950). 181: 4621-31. PMID 18802064 DOI: 10.4049/Jimmunol.181.7.4621 |
0.612 |
|
| 2008 |
Zhou Q, Yan X, Gershan J, Orentas RJ, Johnson BD. Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo. Journal of Immunology (Baltimore, Md. : 1950). 181: 1877-86. PMID 18641325 DOI: 10.4049/Jimmunol.181.3.1877 |
0.596 |
|
| 2008 |
Prosser SE, Orentas RJ, Jurgens L, Cohen EP, Hariharan S. Recovery of BK virus large T-antigen-specific cellular immune response correlates with resolution of bk virus nephritis. Transplantation. 85: 185-92. PMID 18212622 DOI: 10.1097/Tp.0B013E31815Fef56 |
0.359 |
|
| 2007 |
Zhou Q, Johnson BD, Orentas RJ. Cellular immune response to an engineered cell-based tumor vaccine at the vaccination site. Cellular Immunology. 245: 91-102. PMID 17543914 DOI: 10.1016/J.Cellimm.2007.04.004 |
0.414 |
|
| 2007 |
Johnson BD, Jing W, Orentas RJ. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 203-14. PMID 17471167 DOI: 10.1097/01.Cji.0000211336.91513.Dd |
0.561 |
|
| 2007 |
Zheng J, Kohler ME, Chen Q, Weber J, Khan J, Johnson BD, Orentas RJ. Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen. Bmc Immunology. 8: 4. PMID 17397536 DOI: 10.1186/1471-2172-8-4 |
0.528 |
|
| 2007 |
Jing W, Orentas RJ, Johnson BD. Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 13: 277-92. PMID 17317581 DOI: 10.1016/J.Bbmt.2006.11.018 |
0.58 |
|
| 2007 |
Orentas R, Jing W, Yan X, Johnson B. 72: Effective immunotherapy for neuroblastoma requires HSCT and T cell transfer Biology of Blood and Marrow Transplantation. 13: 29. DOI: 10.1016/J.Bbmt.2006.12.075 |
0.456 |
|
| 2006 |
Yan X, Orentas RJ, Johnson BD. Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation. Cytokine. 33: 188-98. PMID 16522371 DOI: 10.1016/J.Cyto.2006.01.006 |
0.514 |
|
| 2006 |
Jurgens LA, Khanna R, Weber J, Orentas RJ. Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: A novel strategy for the treatment of Hodgkin's disease and nasopharyngeal carcinoma. Journal of Clinical Immunology. 26: 22-32. PMID 16418800 DOI: 10.1007/S10875-006-6532-1 |
0.514 |
|
| 2006 |
Orentas RJ, Kohler ME, Johnson BD. Suppression of anti-cancer immunity by regulatory T cells: back to the future. Seminars in Cancer Biology. 16: 137-49. PMID 16376101 DOI: 10.1016/J.Semcancer.2005.11.007 |
0.574 |
|
| 2006 |
Jing W, Orentas RJ, Johnson BD. Vaccine-Induced Anti-Neuroblastoma Immunity Early after HSCT Arises in the Presence of Foxp3+CD25+CD4+ T Cells. Blood. 108: 3692-3692. DOI: 10.1182/Blood.V108.11.3692.3692 |
0.595 |
|
| 2006 |
Jing W, Yan X, Orentas R, Johnson B. Syngeneic neuroblastoma cells transiently-transfected with plasmid DNA vectors encoding a panel of immune stimulatory molecules can induce anti-tumor immunity early after BMT Biology of Blood and Marrow Transplantation. 12: 93. DOI: 10.1016/J.Bbmt.2005.11.286 |
0.385 |
|
| 2005 |
Johnson BD, Gershan JA, Natalia N, Zujewski H, Weber JJ, Yan X, Orentas RJ. Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice. Journal of Immunotherapy (Hagerstown, Md. : 1997). 28: 449-60. PMID 16113601 DOI: 10.1097/01.Cji.0000171313.93299.74 |
0.583 |
|
| 2005 |
Gershan JA, Johnson BD, Weber J, Schauer DW, Natalia N, Behnke S, Burns K, Maloney KW, Warwick AB, Orentas RJ. Immediate transfection of patient-derived leukemia: a novel source for generating cell-based vaccines. Genetic Vaccines and Therapy. 3: 4. PMID 15969754 DOI: 10.1186/1479-0556-3-4 |
0.369 |
|
| 2005 |
Jing W, Orentas RJ, Johnson BD. Induction of Tumor Immunity Early after Syngeneic Bone Marrow Transplantation (BMT) by Transient Transfection of Mouse Neuroblastoma with Plasmid DNA Vectors Encoding a Panel of Immune Stimulatory Molecules. Blood. 106: 1308-1308. DOI: 10.1182/Blood.V106.11.1308.1308 |
0.567 |
|
| 2004 |
Yan X, Johnson BD, Orentas RJ. Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo. Immunology. 112: 105-16. PMID 15096190 DOI: 10.1111/J.1365-2567.2004.01853.X |
0.573 |
|
| 2004 |
Rosenblum MD, Olasz E, Woodliff JE, Johnson BD, Konkol MC, Gerber KA, Orentas RJ, Sandford G, Truitt RL. CD200 is a novel p53-target gene involved in apoptosis-associated immune tolerance. Blood. 103: 2691-8. PMID 14644999 DOI: 10.1182/Blood-2003-09-3184 |
0.465 |
|
| 2004 |
Orentas R, Yan X, Natalia N, Johnson B. Tumor-Derived Macrophage Migration Inhibitory Factor (MIF) Inhibits Effective Immune Activation Journal of Immunotherapy. 27: S47. DOI: 10.1097/00002371-200411000-00171 |
0.315 |
|
| 2004 |
Johnson B, Gershan J, Natalia N, Zujewski H, Weber J, Yan X, Orentas R. Nucleofection of Mouse Neuroblastoma Cells with Plasmid DNA Vectors Can Be Used To Generate Novel Cell-Based Tumor Vaccines Journal of Immunotherapy. 27: S24. DOI: 10.1097/00002371-200411000-00087 |
0.405 |
|
| 2004 |
Jurgens L, Gershan J, Weber J, Orentas R. 808. Electro-Tranfection of Epstein-Barr Virus LMP-2 Specific TCRs Provides a Non-Viral Means To Transfer Antigen Specific T-Cell Receptors to Activated PBMC Populations Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.706 |
0.534 |
|
| 2004 |
Gershan JA, Weber JJ, Orentas RJ. 156. Delivery of plasmid DNA to the nucleus using non-viral gene transfection in tumor cell lines and primary tumors Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.080 |
0.44 |
|
| 2003 |
Keever-Taylor CA, Behn B, Konings S, Orentas R, Davies B, Margolis D. Suppression of EBV release from irradiated B lymphoblastoid cell-lines: superior activity of ganciclovir compared with acyclovir. Cytotherapy. 5: 323-335. PMID 12944239 DOI: 10.1080/14653240310002243 |
0.332 |
|
| 2003 |
Johnson BD, Yan X, Schauer DW, Orentas RJ. Dual expression of CD80 and CD86 produces a tumor vaccine superior to single expression of either molecule. Cellular Immunology. 222: 15-26. PMID 12798304 DOI: 10.1016/S0008-8749(03)00079-0 |
0.534 |
|
| 2002 |
Bin Q, Johnson BD, Schauer DW, Casper JT, Orentas RJ. Production of macrophage migration inhibitory factor by human and murine neuroblastoma. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 23: 123-9. PMID 12218292 DOI: 10.1159/000064028 |
0.42 |
|
| 2002 |
Orentas RJ, Schauer D, Bin Q, Johnson BD. Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cellular Immunology. 213: 4-13. PMID 11747351 DOI: 10.1006/Cimm.2001.1864 |
0.484 |
|
| 2001 |
Orentas RJ, Roskopf SJ, Nolan GP, Nishimura MI. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide Clinical Immunology. 98: 220-228. PMID 11161978 DOI: 10.1006/Clim.2000.4977 |
0.451 |
|
| 2000 |
Siddiqi N, Juckett M, Orentas R, Bresnahan B, Hariharan S. ANTI CD-20 MONOCLONAL ANTIBODY TREATMENT FOR POST-TRANSPLANT B-CELL LYMPHOMA.: Abstract# 708 Transplantation. 69. DOI: 10.1097/00007890-200004271-00708 |
0.44 |
|
| 1999 |
Orentas RJ, Rospkopf SJ, Casper JT, Getts RC, Nilsen TW. Detection of Epstein-Barr virus EBER sequence in post-transplant lymphoma patients with DNA dendrimers. Journal of Virological Methods. 77: 153-63. PMID 10092139 DOI: 10.1016/S0166-0934(98)00149-9 |
0.321 |
|
| 1999 |
Orentas R, Casper J. Immunotherapy in pediatric oncology : Into the twenty-first century Immunology and Allergy Clinics of North America. 19: 309-326. DOI: 10.1016/S0889-8561(05)70090-4 |
0.407 |
|
| Show low-probability matches. |